Vera Therapeutics granted stock options and RSUs to 89 new employees under its 2024 Inducement Plan.
Quiver AI Summary
Vera Therapeutics, Inc. announced the granting of inducement awards to eighty-nine new employees, comprising non-qualified stock options to purchase 258,200 shares and restricted stock units (RSUs) for 131,925 shares of Class A common stock. The awards, approved by the Compensation Committee on April 8, 2026, are part of the company's 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $40.33 per share and will vest over four years, while the RSUs will vest annually over the same period. Vera Therapeutics focuses on developing therapies for serious immunological diseases, with its leading candidate, atacicept, aiming to treat conditions like immunoglobulin A nephropathy and lupus nephritis. The company also works on other promising treatments and holds an exclusive license for additional therapeutic innovations.
Potential Positives
- The grant of inducement awards to eighty-nine new employees indicates a significant growth in the workforce, which can enhance the company's capacity for research and development.
- The stock options and RSUs granted as part of the Inducement Plan serve to align the interests of new employees with the company's performance, potentially fostering a motivated workforce aimed at driving company success.
- The awards are granted under terms that ensure a strong employee commitment, with a vesting schedule that promotes retention over four years.
- Vera Therapeutics continues to advance its clinical-stage portfolio, which includes innovative treatments targeting serious immunological diseases, indicating a strong commitment to addressing unmet medical needs.
Potential Negatives
- The issuance of a significant number of stock options and restricted stock units to 89 new employees may raise concerns about potential dilution of existing shareholders' equity.
- Vera Therapeutics may face scrutiny regarding its reliance on inducement awards to attract new talent, which could signal challenges in attracting qualified candidates without such incentives.
- Stock options priced at the current market value might indicate limited immediate upside for new employees, potentially impacting their motivation and perceived value of the award.
FAQ
What stock options were granted by Vera Therapeutics?
The Compensation Committee granted inducement awards of non-qualified stock options to purchase 258,200 shares of Class A common stock.
When were the stock options awarded?
The stock options were awarded on April 8, 2026, as part of the Inducement Plan.
What is the vesting schedule for the stock options?
The stock options will vest over four years, with 25% vesting on the first anniversary and monthly thereafter for 36 months.
Who received the inducement awards?
Inducement awards were granted to eighty-nine new employees of Vera Therapeutics.
What is Vera Therapeutics' main focus?
Vera Therapeutics is focused on developing treatments for serious immunological diseases, particularly targeting sources of disease for better patient care.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VERA Insider Trading Activity
$VERA insiders have traded $VERA stock on the open market 13 times in the past 6 months. Of those trades, 1 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $VERA stock by insiders over the last 6 months:
- WILLIAM D. TURNER (Chief Regulatory Officer) has made 0 purchases and 4 sales selling 32,187 shares for an estimated $1,445,638.
- MARSHALL FORDYCE (PRESIDENT AND CEO) sold 16,925 shares for an estimated $710,577
- JOSEPH R YOUNG (SVP, FINANCE, CHIEF ACCT OFFCR) has made 0 purchases and 2 sales selling 18,117 shares for an estimated $566,738.
- PATRICK G ENRIGHT purchased 5,882 shares for an estimated $249,985
- SEAN GRANT (CHIEF FINANCIAL OFFICER) sold 4,949 shares for an estimated $207,778
- DAVID LEE JOHNSON (Chief Operating Officer) sold 2,579 shares for an estimated $108,276
- JASON S CARTER (Chief Legal Officer) sold 3,864 shares for an estimated $107,498
- ROBERT BRENNER (Chief Medical Officer) sold 2,151 shares for an estimated $90,307
- LAURENCE MATTHEW SKELTON (Chief Commercial Officer) sold 1,582 shares for an estimated $66,418
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$VERA Hedge Fund Activity
We have seen 128 institutional investors add shares of $VERA stock to their portfolio, and 80 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 2,821,135 shares (+inf%) to their portfolio in Q4 2025, for an estimated $142,862,276
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,795,537 shares (+49.0%) to their portfolio in Q4 2025, for an estimated $90,925,993
- BELLEVUE GROUP AG added 1,698,152 shares (+inf%) to their portfolio in Q4 2025, for an estimated $85,994,417
- TANG CAPITAL MANAGEMENT LLC removed 1,350,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $68,364,000
- HOLOCENE ADVISORS, LP added 1,307,393 shares (+inf%) to their portfolio in Q4 2025, for an estimated $66,206,381
- ALLIANCEBERNSTEIN L.P. added 1,166,066 shares (+2217.2%) to their portfolio in Q4 2025, for an estimated $59,049,582
- CITADEL ADVISORS LLC removed 837,850 shares (-51.9%) from their portfolio in Q4 2025, for an estimated $42,428,724
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$VERA Analyst Ratings
Wall Street analysts have issued reports on $VERA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 12/19/2025
- Goldman Sachs issued a "Buy" rating on 12/19/2025
- JP Morgan issued a "Overweight" rating on 12/19/2025
- TD Cowen issued a "Buy" rating on 12/05/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
To track analyst ratings and price targets for $VERA, check out Quiver Quantitative's $VERA forecast page.
$VERA Price Targets
Multiple analysts have issued price targets for $VERA recently. We have seen 8 analysts offer price targets for $VERA in the last 6 months, with a median target of $91.5.
Here are some recent targets:
- Andy Chen from Wolfe Research set a target price of $88.0 on 03/11/2026
- Arthur He from HC Wainwright & Co. set a target price of $110.0 on 03/02/2026
- Dina Ramadane from B of A Securities set a target price of $66.0 on 12/19/2025
- Paul Choi from Goldman Sachs set a target price of $95.0 on 12/19/2025
- Anupam Rama from JP Morgan set a target price of $96.0 on 12/19/2025
- Laura Chico from Wedbush set a target price of $33.0 on 12/11/2025
- Gavin Clark-Gartner from Evercore ISI Group set a target price of $97.0 on 12/08/2025
Full Release
BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 258,200 shares of Class A common stock and restricted stock units (RSUs) underlying 131,925 shares of Class A common stock to eighty-nine (89) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option granted on April 8, 2026 has an exercise price per share equal to $40.33, Vera Therapeutics’ closing trading price on April 8, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of May 20, 2026, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About
Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit
www.veratx.com
.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
[email protected]
Media
Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
[email protected]
